Top
Note: You're navigating the results of models obtained with the previous release of IntOGen (2020). A new boostDM version corresponding to the current IntOGen release will be available soon.
TP53 17:7675188:T (P142T) ×
Driver potential
Model BoostDM class BoostDM score
(AML) Acute myeloid leukemia Passenger 0.17
(BLCA) Bladder cancer Passenger 0.38
(BRCA) Breast adenocarcinoma Driver 0.99
(CH) Cholangiocarcinoma Driver 0.88
(CLL) Chronic lymphoblastic leukemia Passenger 0.23
(CM) Cutaneous melanoma of the skin Passenger 0.07
(COREAD) Colorectal adenocarcinoma Passenger 0.07
(DLBCL) Diffuse large B-cell lymphoma Driver 0.62
(ESCA) Esophageal cancer Passenger 0.04
(GBM) Glioblastoma Driver 0.64
(HC) Hepatic cancer Passenger 0.19
(HGG) High-grade glioma Passenger 0.07
(HNSC) Head and neck squamous cell carcinoma Passenger 0.01
(LEIS) Leiomyosarcoma Passenger 0.30
(LGG) Lower grade glioma Driver 0.99
(LUAD) Lung adenocarcinoma Passenger 0.05
(LUNG_CANCER) Lung cancer Passenger 0.22
(LUSC) Lung squamous cell carcinoma Passenger 0.07
(LY) Lymphoma Passenger 0.36
(MM) Multiple myeloma Passenger 0.31
(NHLY) Non-hodking lymphoma Driver 0.60
(OS) Osteosarcoma Driver 0.53
(OV) Ovary cancer Passenger 0.01
(PAAD) Pancreas adenocarcinoma Passenger 0.06
(PIA) Pilocityc astrocytoma Passenger 0.00
(PRAD) Prostate adenocarcinoma Passenger 0.03
(R) Kidney cancer Passenger 0.20
(RCCC) Renal clear cell carcinoma Passenger 0.20
(RCH) Chromophobe renal cell carcinoma Passenger 0.07
(S) Sarcoma Passenger 0.30
(SCLC) Small-cell lung cancer Passenger 0.02
(ST) Stomach adenocarcinoma Passenger 0.09
(UCEC) Endometrial cancer Passenger 0.02
(UCS) Uterine carcinosarcoma Passenger 0.26
Select a tumor type to check the corresponding model Show the legend